Bioventix Dividends - BVXP

Stock Name	Stock Symbol	Market	Stock Type
Bioventix Plc	BVXP	London	Ordinary Share

	Price Change	Price Change %	Stock Price	Last Trade
	25.00	0.64%	3,945.00	12:32:18

Open Price	Low Price	High Price	Close Price	Previous Close
3,925.00	3,925.00	3,945.00	3,945.00	3,920.00

more quote information »

Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Bioventix BVXP Dividends History

Announcement Date	Type	Currency	Dividend Amount	Period Start	Period End	Ex Date	Record Date	Payment Date	Total Dividend Amount
29/03/2022	Interim	GBX	52	01/07/2021	31/12/2021	07/04/2022	08/04/2022	22/04/2022	0
18/10/2021	Special	GBX	38	30/06/2020	30/06/2021	28/10/2021	29/10/2021	12/11/2021	0
18/10/2021	Interim	GBX	62	30/06/2020	30/06/2021	28/10/2021	29/10/2021	12/11/2021	105
29/03/2021	Interim	GBX	43	01/07/2020	31/12/2020	08/04/2021	09/04/2021	23/04/2021	0
19/10/2020	Special	GBX	53	30/06/2019	30/06/2020	29/10/2020	30/10/2020	13/11/2020	0
19/10/2020	Interim	GBX	52	30/06/2019	30/06/2020	29/10/2020	30/10/2020	13/11/2020	78
30/03/2020	Interim	GBX	36	01/07/2019	31/12/2019	09/04/2020	14/04/2020	28/04/2020	0
21/10/2019	Interim	GBX	43	30/06/2018	30/06/2019	31/10/2019	01/11/2019	15/11/2019	73
21/10/2019	Special	GBX	47	30/06/2018	30/06/2019	31/10/2019	01/11/2019	15/11/2019	0
29/03/2019	Interim	GBX	30	01/07/2018	31/12/2018	11/04/2019	12/04/2019	26/04/2019	0
08/10/2018	Interim	GBX	36	30/06/2017	30/06/2018	25/10/2018	26/10/2018	09/11/2018	61
08/10/2018	Special	GBX	55	30/06/2017	30/06/2018	25/10/2018	26/10/2018	09/11/2018	0
26/03/2018	Interim	GBX	25	01/07/2017	31/12/2017	05/04/2018	06/04/2018	20/04/2018	0
16/10/2017	Interim	GBX	31	30/06/2016	30/06/2017	26/10/2017	27/10/2017	10/11/2017	51
16/10/2017	Special	GBX	20	30/06/2016	30/06/2017	26/10/2017	27/10/2017	10/11/2017	0
27/03/2017	Interim	GBX	20	01/07/2016	31/12/2016	06/04/2017	07/04/2017	21/04/2017	0
17/10/2016	Interim	GBX	26	30/06/2015	30/06/2016	27/10/2016	28/10/2016	11/11/2016	42.5
17/10/2016	Special	GBX	20	30/06/2015	30/06/2016	27/10/2016	28/10/2016	11/11/2016	0
21/03/2016	Interim	GBX	16.5	01/07/2015	31/12/2015	07/04/2016	08/04/2016	22/04/2016	0
05/10/2015	Final	GBX	21.6	30/06/2014	30/06/2015	15/10/2015	16/10/2015	30/10/2015	32.6
30/03/2015	Interim	GBX	11	01/07/2014	31/12/2014	09/04/2015	10/04/2015	24/04/2015	0
07/10/2014	Final	GBX	14.4	30/06/2013	30/06/2014	16/10/2014	17/10/2014	31/10/2014	24
24/04/2014	Interim	GBX	9.6	01/07/2013	31/12/2013	08/05/2014	09/05/2014	27/05/2014	0

Top Dividend Posts

Top Posts
Posted at 03/1/2023 22:46 by strollingmolby Not sure I saw this posted from early-December - Keith Ashworth-Lord in the IC: Https://www.investorschronicle.co.uk/news/2022/12/09/shares-i-love-bioventix/ "Keith Ashworth-Lord, chief investment officer of Sanford DeLand Asset Management and manager of CFP SDL UK Buffettology Fund (GB00BF0LDZ31), explains why he invests in antibody producer Bioventix (BVXP). "Bioventix is one of the most attractive businesses in the Buffettology portfolio. It occupies a genuine niche where the economic moat [competitive advantages] is protected by regulatory affairs, in particular the need for product approval from regulators on both sides of the Atlantic, which can take several years to obtain. "The product concerned is high affinity, monoclonal antibodies harvested from sheep. When you go to a GP for a blood test, your sample containing antigens gets mixed with a reagent containing antibodies. This is then read by a machine to determine if you have any conditions, such as vitamin D deficiency. Bioventix sells its product to the big five machine manufacturers and in return gets a royalty – typically 2 per cent – every time a test is done on its machine. For the manufacturer, the royalty is a relatively small proportion of cost and as long as the antibody is working, why take the risk of moving to an unproven rival product? Growth has been consistent over the past 12 years with a compound annual growth rate in revenue of 10.1 per cent over the past five years and 17.3 per cent over the past 10 years. The slowdown is because its revenues from a major antibody terminated after 10 years, as planned, in August 2021 with the loss of £1.2mn in sales. In its last financial year, gross margin was 93.9 per cent and operating margin was 79.1 per cent – this is a product with very little cost of sales attached. "The wealth of the business rests with its employees' expertise, of which there are just 17 in total. Per capita sales and profit are an astonishing £690,000 and £545,000, respectively. Being an asset-light business, the return on average equity is 63.8 per cent and the conversion of profit after tax to free cash flow has averaged at 101 per cent over the past five years. With its major costs being research and development, and staff, Bioventix is able to pay generous dividends. Including supplementary dividends, all and more of earnings per share (EPS) have been returned to shareholders for five years without fail." Read Full Thread Follow Reply
Posted at 29/12/2022 12:15 by maddox Excellent to see this paper published - and remarkably promising results. The prospects for a BVXP developed blood test for Alzheimer’s disease thus look optimistic. It works, I think it's just a question of how well and how well in clinical application? A test for Alzheimer's also needs an effective treatment otherwise not going to much used outside of the research field. This looks like a highly significant step-forward in addressing this awful disease. if any of you like myself have had relatives suffer from Alzheimer's will know just how miserable it is. Congratulations to the research team! Read Full Thread Follow Reply
Posted at 06/12/2022 21:26 by maddox Hi qvg, The paper casts doubt over the efficacy of reducing Tau as a means of preventing degenerative decline. Whereas Gothenburg Uni/BVXP are focussing on using Tau as a marker predicting dementia at an early stage rather than as a target for treatment. The paper cites Ossenkoppele et al., 2021, 'Tau accumulation is a terminal event in neurodegenerative disorders, and because the increase of CSF tau in patients with AD occurs closer to the onset of neurodegeneration than does the decrease of Aβ42, tau has been shown to correlate to a greater extent with dementia than Aβ42, with tau aggregates predicting dementia better than Aβ deposits' The paper is thus supportive of Tau as a predictor of dementia, and hopefully its use in a simple blood test for wide spread screening. Read Full Thread Follow Reply
Posted at 30/11/2022 17:21 by maddox Great news today on the potential treatment of Alzheimers with drug lecanemab from manufacturers Eisai and Biogen. One of the problems with a new drug such as this is how do you identify potential patients at an early stage of dementia that will benefit from treatment. A lumber puncture or a PET scan are the current means of diagnosis - which are impractical. This is where BVXP has a promising alternative diagnostic. As stated in the recent results: 'a biomarker that has shown potential in Alzheimer’s diagnostics is the Tau protein in the form of total Tau and phosphorylated Tau. During the year we created more anti-Tau antibodies and this work will continue into 2023. Our academic collaborators at the University of Gothenburg have used our antibodies to create prototype assays and have generated encouraging data from patient blood samples. The levels of Tau detected using our antibodies are approximately 2 times higher in Alzheimer’s samples compared to controls, a ratio of 2 times being similar to other research groups. Our scientific target ratio is slightly higher at 4-5 times. We are encouraged by this progress and plan to create more antibodies to support further work with our collaborators in Gothenburg during 2023. The recent success of the Eisai/Biogen lecanemab clinical trial is likely to increase the need for early diagnostics and we are very fortunate to be working with one of the world’s leading labs focussed on Alzheimer’s biomarkers and tests.' Read Full Thread Follow Reply
Posted at 23/11/2022 09:18 by robow from Citywire Ashworth-Lord: Bioventix offers ‘astonishing’ equity return Bioventix (BVXP), a specialist developer of sheep antibodies, has delivered an ‘astonishing’ return on equity over five years, according to Sanford DeLand fund manager Keith Ashworth-Lord. Ashworth-Lord, who holds Farnham-based Bioventix in his £855m CFP SDL UK Buffettology fund, said in his latest commentary that the stock remained unchanged ‘despite an outstanding set of results for the financial year ending June 2022’. Sales were up 7% as its vitamin D antibody returned to ‘double-digit growth’, leading to a 15% increase in operating profit and the operating margin expanding 79%. ‘That is not a typo,’ said Ashworth-Lord. ‘After-tax earnings increased by 15% and 98% of those earnings were converted into free cashflow, which helped to fund a 20% increase in the ordinary dividend and another special dividend.’ He said capital requirements were ‘very limited’ and over the past five years ‘Bioventix has managed to increase after-tax earnings by £2.8m, while the amount of equity capital employed in the business has increased by just £1.7m’. ‘The incremental return on equity over the past five years is an astonishing 164%,’ he said. Bioventix fell 1.4% yesterday to close 50p lower at £36.50. They have risen 7.4% this year and are up 38% over five years, valuing the company at £190m. Read Full Thread Follow Reply
Posted at 24/10/2022 11:44 by stepone68 Margins remain high. Cost of sales for some reason dropped over 100k compared to the previous 3 years. EPS and divi both around 150p, which was what I was hoping for, leaving P/E ratio around 23 and yield 4.4%. Doesn't look too expensive for a growing company. Troponin almost doubled (again!). Hope that trajectory continues - they seem to think it might. They also seem confident on their pipeline of research projects which will delivery revenue 2026-36. Sounds good to me. Read Full Thread Follow Reply
Posted at 26/9/2022 09:57 by stepone68 Depends on what fx rates analysts have been using in their forecasts, and how much they have changed. Possibly not that much (i.e. they were already lower than spot rate). Plus other companies will also benefit from the weak pound, not just BVXP. Read Full Thread Follow Reply
Posted at 15/9/2022 09:51 by stepone68 Well, because I've got nothing better to do, I looked back at previous updates. The last one, as mentioned above, was 2017 ! In it, they said, "revenues for the financial year ended 30 June 2017 are expected to be marginally in excess of £7M (2015/16: £5.5M). Since the cost-base of the Company continues to follow a similar shallow trajectory as in previous years, both revenues and profits before tax are expected to be ahead of market expectations for the year ended 30 June 2017" So, they actually gave a figure for turnover there! Looking at my notes, forecasts in 2017 were saying revenues of 6.3m. After the update, forecasts were showing 7.06m. The actual came in at 7.25m. So that looks like a bit over 10% to me, and they only said 'ahead' (i.e. no mention of 'materially' or 'significantly'). In August 2016 they also gave a revenue number - "in excess of 5.3m", and once again simply said profits would be "ahead". Forecasts had been saying £4.8m. So, again it looks like they were about 10% ahead, and, in the end, turnover was £5.5m. In both those years, though, the high margins meant that EPS was 30-40% above forecasts. This year, they did use the word 'significantly', so we should surely expect at least 10%, if not more! So, I'm going to take a punt on 11.4m turnover, eps 150p, dividend 150p - and I'm actually hoping for slightly more!! Fingers crossed, StepOne Read Full Thread Follow Reply
Posted at 28/3/2022 08:21 by piedro Interims ... "Board is pleased to announce a first interim dividend of 52p per share which represents a 20% increase on the interim dividend paid last year (43 pence per share). The shares will be marked ex-dividend on the 7 April 2021 and the dividend will be paid on 22 April 2021 to shareholders on the register at close of business on 8 April 2021." !! Read Full Thread Follow Reply
Posted at 11/11/2021 16:02 by jonut Full list of bvxp rns's here, https://www.investegate.co.uk/Index.aspx?searchtype=3&words=bvxp Read Full Thread Follow Reply

Your Recent History

LSE

BVXP

Bioventix

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Advertise Here

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US

P: V: D:20230129 05:15:11